Stevanato Group appoints Ugo Gay as Chief Operations Officer
04 Aprile 2024 - 2:00PM
Business Wire
Strengthening corporate leadership aims to drive operational
efficiencies and standardization of global processes.
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider
of drug containment, drug delivery, and diagnostic solutions to the
pharmaceutical, biotechnology, and life science industries, today
announced the appointment of Ugo Gay as its new Chief Operations
Officer (COO).
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240404727049/en/
Ugo Gay appointed as Chief Operations
Officer of Stevanato Group (Photo: Business Wire)
The addition of Ugo Gay underscores Stevanato Group’s unwavering
commitment to driving operational efficiency, process
standardization, and sustainable growth across its global value
chain.
Ugo Gay brings to Stevanato Group nearly three decades of
experience in industry, business management, supply chain, and
operations. Prior to joining Stevanato Group, Ugo held key
leadership positions at renowned organizations, including the
Biological Chemotherapy Institute of Turin and Diasorin, an Italian
multinational biotechnology company. At Diasorin, Ugo served in
various roles, from Sales to Industrial Operations, culminating in
his tenure as CEO and General Manager of the new subsidiary
Diasorin Italia S.p.A.
In his new role as COO of Stevanato Group, Ugo Gay will shape
and execute sourcing, planning, and manufacturing strategies to
help drive the Company's growth and achieve its business goals and
vision. With a keen focus on maximizing returns on investments and
driving efficiencies, Ugo will oversee priority strategic projects
and lead the development and management of information systems to
support the Company's development and standardization of
processes.
“We are thrilled to welcome Ugo Gay to our leadership team,”
said Franco Moro, CEO at Stevanato Group. “Ugo's wealth of
experience and proven track record in driving operational
excellence and growth will be invaluable as we continue to expand
and innovate in the pharma, biopharma, and life science sectors.
His appointment reflects our commitment to building a world-class
team capable of delivering sustainable success.”
Ugo Gay officially assumed his role as Chief Operations Officer
on March 25, 2024, and will be based at Piombino Dese.
“I am honored to help lead Stevanato Group's journey towards
operational excellence, driving sustainable growth across our
global footprint while fostering innovation," said Ugo Gay, Chief
Operations Officer at Stevanato Group.
Forward-Looking Statements
This press release may include forward-looking statements. The
words "aims," “driving,” "will," “shape,” “execute,” “drive,”
“achieve,” “continue,” “expand,” and similar expressions (or their
negative) identify certain of these forward-looking statements.
These forward-looking statements are statements regarding the
Company's intentions, beliefs or current expectations concerning,
among other things, the investments the Company expects to receive,
the expansion of manufacturing capacity, the Company’s plans
regarding its presence in the U.S. market, business strategies, the
Company’s capacity to meet future market demands and support
preparedness for future public health emergencies, and results of
operations. The forward-looking statements in this press release
are based on numerous assumptions regarding the Company’s present
and future business strategies and the environment in which the
Company will operate in the future. Forward-looking statements
involve inherent known and unknown risks, uncertainties and
contingencies because they relate to events and depend on
circumstances that may or may not occur in the future and may cause
the actual results, performance or achievements of the Company to
be materially different from those expressed or implied by such
forward looking statements. Many of these risks and uncertainties
relate to factors that are beyond the Company's ability to control
or estimate precisely, such as future market conditions, currency
fluctuations, the behavior of other market participants, the
actions of regulators and other factors such as the Company's
ability to continue to obtain financing to meet its liquidity
needs, changes in the political, social and regulatory framework in
which the Company operates or in economic or technological trends
or conditions. Readers should therefore not place undue reliance on
these statements, particularly not in connection with any contract
or investment decision. Except as required by law, the company
assumes no obligation to update any such forward-looking
statements.
About Stevanato Group
Founded in 1949, Stevanato Group is a leading global provider of
drug containment, drug delivery and diagnostic solutions to the
pharmaceutical, biotechnology and life sciences industries. The
Group delivers an integrated, end-to-end portfolio of products,
processes and services that address customer needs across the
entire drug life cycle at each of the development, clinical and
commercial stages. Stevanato Group’s core capabilities in
scientific research and development, its commitment to technical
innovation and its engineering excellence are central to its
ability to offer value added solutions to clients. To learn more,
visit: www.stevanatogroup.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240404727049/en/
Media relations: media@stevanatogroup.com
Investor relations: Lisa Miles:
lisa.miles@stevanatogroup.com
Team Lewis for Stevanato Group: Cassie Gonzales:
stevanatoUS@teamlewis.com Nicolò Marcon, Arianna Cusolito:
stevanatoita@teamlewis.com
Grafico Azioni Stevanato (NYSE:STVN)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Stevanato (NYSE:STVN)
Storico
Da Dic 2023 a Dic 2024
